$27.99
2.27% yesterday
Nasdaq, Aug 11, 10:00 pm CET
ISIN
US92337F1075
Symbol
VCYT

Veracyte Inc Stock price

$27.99
+0.91 3.36% 1M
-12.98 31.68% 6M
-11.61 29.32% YTD
-1.93 6.45% 1Y
+2.50 9.81% 3Y
-4.60 14.11% 5Y
+18.22 186.49% 10Y
+14.74 111.25% 20Y
Nasdaq, Closing price Mon, Aug 11 2025
+0.62 2.27%
ISIN
US92337F1075
Symbol
VCYT
Industry

Key metrics

Basic
Market capitalization
$2.2b
Enterprise Value
$1.9b
Net debt
-
Cash
$320.7m
Shares outstanding
78.3m
Valuation (TTM | estimate)
P/E
84.8 | 54.0
P/S
4.6 | 4.4
EV/Sales
3.9 | 3.7
EV/FCF
22.4
P/B
1.8
Financial Health
Equity Ratio
90.5%
Return on Equity
2.1%
ROCE
2.9%
ROIC
3.4%
Debt/Equity
-
Financials (TTM | estimate)
Revenue
$479.1m | $501.8m
EBITDA
$44.6m | $112.6m
EBIT
$37.3m | $36.0m
Net Income
$26.3m | $40.6m
Free Cash Flow
$84.0m
Growth (TTM | estimate)
Revenue
19.9% | 12.6%
EBITDA
128.8% | 299.7%
EBIT
52,395.8% | 84.4%
Net Income
148.7% | 68.2%
Free Cash Flow
109.2%
Margin (TTM | estimate)
Gross
68.3%
EBITDA
9.3% | 22.4%
EBIT
7.8%
Net
5.5% | 8.1%
Free Cash Flow
17.5%
More
EPS
$0.3
FCF per Share
$1.1
Short interest
8.7%
Employees
824
Rev per Employee
$540.0k
Show more

Is Veracyte Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,025 stocks worldwide.

Veracyte Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

18 Analysts have issued a Veracyte Inc forecast:

15x Buy
83%
2x Hold
11%
1x Sell
6%

Analyst Opinions

18 Analysts have issued a Veracyte Inc forecast:

Buy
83%
Hold
11%
Sell
6%

Financial data from Veracyte Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
479 479
20% 20%
100%
- Direct Costs 152 152
22% 22%
32%
327 327
19% 19%
68%
- Selling and Administrative Expenses 213 213
11% 11%
44%
- Research and Development Expense 70 70
10% 10%
15%
45 45
129% 129%
9%
- Depreciation and Amortization 7.32 7.32
62% 62%
2%
EBIT (Operating Income) EBIT 37 37
52,396% 52,396%
8%
Net Profit 26 26
149% 149%
5%

In millions USD.

Don't miss a Thing! We will send you all news about Veracyte Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Veracyte Inc Stock News

Neutral
Seeking Alpha
5 days ago
Veracyte, Inc. (NASDAQ:VCYT ) Q2 2025 Earnings Conference Call August 6, 2025 4:30 PM ET Company Participants Marc A. Stapley - CEO & Director Phillip G.
Positive
The Motley Fool
5 days ago
Veracyte (VCYT) Q2 Revenue Jumps 14%
Neutral
Business Wire
6 days ago
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced financial results for the second quarter ended June 30, 2025. “Testing growth continues to exceed our expectations, driven by Decipher which achieved its thirteenth consecutive quarter of over 25% year-over-year volume growth,” said Marc Stapley, Veracyte's chief ex...
More Veracyte Inc News

Company Profile

Veracyte, Inc. engages in the research, development and commercialization of diagnostic products. The firm's portfolio includes Afirma, Percepta, and Envisia. It intends to treat thyroid cancer, improve lung cancer screening, and clarify the diagnosis of idiopathic pulmonary fibrosis. The company was founded by Bonnie H. Anderson and Y. Douglas Dolginow on August 15, 2006 and is headquartered in South San Francisco, CA.

Head office United States
CEO Marc Stapley
Employees 824
Founded 2006
Website www.veracyte.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today